CA-WILSHIRE/XTP
29.8.2024 15:01:32 CEST | Business Wire | Press release
Wilshire Advisors LLC (“Wilshire”), a leading global financial services firm, today announced that it has joined forces with XTP Implementation Services (“XTP”), a tech-enabled and data-driven specialist focused on improving transparency, reducing risk, enhancing investment governance, and increasing net returns for institutional investors globally. Through this partnership, which was effectuated by an acquisition of XTP by Wilshire, with simultaneous reinvestment in Wilshire by former XTP shareholders, XTP will continue to operate independently under its existing leadership team and brand. Financial terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828886722/en/
XTP is a market leader in cost transparency analytics, with a 20-year history of serving public and private investors, including pension funds, insurance companies, sovereign wealth funds, investment consultants, outsourced chief investment officers, endowments and foundations, and family offices. With more than $3 trillion in assets analyzed across 10,000 portfolios in North America and Europe, XTP helps its clients reduce investment-related costs and risks while enhancing governance. Combining deep industry experience and proprietary software, benchmarking databases, and forensic capabilities allows XTP to identify optimization potential across the investment value chain of public and private market portfolios. XTP clients benefit from a risk-free increase in net returns.
Andy Stewart, CEO at Wilshire, said: “We are excited to partner with XTP and bring its cost and risk-reduction services to our institutional clients, which will benefit from the power of its sophisticated insights and solutions. Throughout our discussions, it was clear that Wilshire and XTP share a holistic, client-centric approach that seeks to align our success with that of our clients. On behalf of Wilshire, I extend a warm welcome to the talented XTP team and look forward to collaborating for the benefit of our combined client base.”
Philipp Henrich, Founder and CEO at XTP, said: “We welcome our partnership with Wilshire, whose solutions, clients, and geographic footprint are complementary to ours. By joining forces, we have the opportunity to leverage the resources of a global service provider with a very strong presence in North America. This will enable us to offer our capabilities to an expanded client base while continuing to provide our valued, long-standing customers personalized, mission-critical support. We could not be more optimistic about this new, bright chapter for XTP with Wilshire alongside us.”
Jason Schwarz, President and Deputy CEO at Wilshire, said: “Institutional investors worldwide are more focused than ever on efficiency and transparency, seeking to better understand, disclose, and manage the true costs of their investments. XTP has an impressive 20-year track record and unmatched ability to identify cost and risk-reduction opportunities and translate those insights into enhanced returns. By bringing together XTP’s proprietary capabilities and Wilshire’s multifaceted platform, we will be even better positioned to empower clients with solutions that address their top concerns and deliver even more value.”
Solomon Partners and Kirkland & Ellis LLP served as financial advisor and legal advisor to Wilshire, respectively. XTP shareholders were advised by DLA Piper.
About Wilshire
Wilshire is a leading global financial services firm and trusted partner to approximately 500 leading institutional investors and financial intermediaries. Our clients rely on us to improve investment outcomes for a better future. Wilshire advises on over $1.4 trillion in assets and manages over $121 billion in assets as of March 31, 2024. Wilshire is headquartered in the United States with offices worldwide. More information on Wilshire can be found at www.wilshire.com.
About XTP
XTP is a specialist consultant focusing on transparency, cost, and risk. XTP actively supports large institutional asset owners globally in turning data into measurable results. By creating full cost transparency in public and private market portfolios XTP assures contract compliance, eliminates process inefficiencies and operation risks, and optimizes costs without changing the existing investment set-up. More information on XTP can be found at www.xtp-group.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828886722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
